In vivo therapeutic success of MicroRNA-155 antagomir in a mouse model of pulmonary fibrosis induced by bleomycin

Background/Aims MicroRNAs (miRNAs) play critical regulatory roles in the pathogenesis of pulmonary fibrosis. The aim this study was to explore whether miRNA antagomirs could serve as potential therapeutic agents interstitial lung diseases. Methods A mouse model fibrosis established by intratracheal injection bleomycin (BLM). Using microarray analysis, up-regulated miRNAs were identified during development miR-155 chosen candidate miRNA. Fifteen mice then randomized into following three groups: BLM + antagomiR-155 group, treated with plus intravenously injected antagomiR-155; phosphate-buffered saline (PBS); and a control PBS only. Lung tissues collected for histopathological hydroxyproline measurement, Western blotting. Enzyme-linked immunosorbent assays used measurement cytokines associated Results Histological changes levels induced significantly inhibited antagomiR-155. interleukin 4 (IL-4) transforming growth factor-β (TGF-β) expression increased after treatment. However, silencing decreased IL-4, TGF-β, interferon-γ. TGF-β-activated kinase 1/mitogen-activated protein 7 (MAP3K7)-binding 2 (TAB2) mitogen-activated (MAPK) signaling pathway, activated vivo via Conclusions In treatment alleviated pathological may be promising strategy